New research from BIDMC and Stanford reveals how nasal polyps form in chronic sinusitis, offering hope for improved care and treatment options. Read more.

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from ...

About The Study: Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart, a novel monoclonal antibody, reduced polyp size and ...

An FDA Decision for Amgen and AstraZeneca’s Tezspire in CRSwNP is slated for October 19: Why Approval Looks Likely.

Verekitug is the only known thymic stromal lymphopoietin receptor antagonist. Doses were given at baseline and at 12 weeks. Verekitug’s use in asthma and COPD will be studied next. Two doses of ...

– In this 24-week study, VIBRANT met its primary endpoint, with verekitug dosed every 12 weeks leading to a statistically significant and clinically meaningful reduction from baseline in ...

A randomized placebo-controlled Finnish study showed that aspirin therapy does not provide significant relief for people suffering from chronic rhinosinusitis with nasal polyps who are hypersensitive ...

Chronic rhinosinusitis (CRS) is a surprisingly common but under-recognized disease that affects nearly one billion people ...

For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid, the randomized CROWNS-2 trial showed. When ...

Please provide your email address to receive an email when new articles are posted on . Nasal polyp and congestion scores dropped more with stapokibart vs. placebo. Overall nasal symptoms, sense of ...